Chlamydophila pneumoniae Antibodies (IgG, IgA, IgM)
The Chlamydophila pneumoniae Antibodies panel measures serum IgG, IgA, and IgM against an obligate intracellular bacterium causing atypical community-acquired pneumonia and investigated in chronic respiratory and inflammatory syndromes. High adult seroprevalence, assay variability, and cross-reactivity complicate interpretation;
3
Biomarkers
Blood (serum)
Sample
3–5 business days
Turnaround
No
Fasting
What is the C. pneumoniae Antibodies test?
The Chlamydophila pneumoniae Antibodies panel measures serum IgG, IgA, and IgM against an obligate intracellular bacterium responsible for community-acquired pneumonia, bronchitis, and pharyngitis, and investigated as a contributor to chronic inflammatory conditions including asthma exacerbation, atherosclerosis, and reactive arthritis. Serology remains the most widely available laboratory method for C. pneumoniae, though its interpretation is complicated by high background seroprevalence, cross-reactivity with other chlamydial species, and the lack of a universally standardised assay. Practitioners order this panel to support the diagnosis of atypical pneumonia when clinical and radiological features suggest it, to investigate persistent or recurrent respiratory symptoms where chronic infection is suspected, and less commonly to explore associations with extra-pulmonary inflammatory syndromes. Because single titres are difficult to interpret in isolation, the panel is most informative when acute and convalescent samples are compared or when all three immunoglobulin classes are measured together to profile the stage and chronicity of infection.
What does the C. pneumoniae Antibodies test measure?
IgG antibodies to Chlamydophila pneumoniae appear several weeks after primary infection and persist for years, often at detectable titres following resolution of acute illness. IgG may also rise during reinfection or chronic carriage, making it a marker of both past exposure and potentially ongoing or reactivated infection depending on titre and clinical context.
Elevated IgG indicates past or chronic C. pneumoniae exposure. Because seroprevalence in adults is high, a single positive IgG is not diagnostic of acute infection but may support chronic or recurrent respiratory illness when interpreted alongside IgA and IgM. Serial rising titres strengthen the diagnosis of recent infection.
IgA antibodies develop within weeks of primary infection and during reinfection, and their presence or elevation is thought to reflect active or recent mucosal immune response. Persistent IgA positivity has been interpreted as a marker of chronic or reactivated infection in some clinical contexts, though the specificity of this finding remains debated.
Positive or rising IgA is often regarded as evidence of active, recent, or chronic C. pneumoniae infection. Its detection alongside elevated IgG or IgM strengthens suspicion of ongoing disease, particularly in chronic respiratory or systemic inflammatory syndromes where persistent intracellular infection is postulated.
IgM is the earliest antibody class to appear in primary C. pneumoniae infection, typically within the first two to three weeks, and declines over subsequent months. IgM may be absent or weak in reinfection, where an anamnestic IgG and IgA response predominates, limiting its reliability as a marker of acute infection in adults with prior exposure.
Positive IgM suggests acute or very recent primary infection, though sensitivity is modest and false positives occur. In the setting of prior exposure, reinfection may not trigger detectable IgM, so its absence does not exclude active disease. Interpret IgM alongside IgG and IgA, clinical presentation, and serial titres rather than as a standalone acute-phase marker.
Why is the C. pneumoniae Antibodies test ordered?
- Investigation of atypical community-acquired pneumonia with cough, low-grade fever, and interstitial infiltrates, particularly when Mycoplasma serology is also ordered
- Evaluation of chronic or recurrent respiratory symptoms — persistent cough, bronchitis, or asthma exacerbation — where intracellular bacterial infection is considered
- Suspected reactive arthritis or extra-pulmonary manifestations following respiratory illness, interpreted with clinical and microbiological context
- Research or exploratory assessment of cardiovascular atherosclerotic disease, though routine screening for C. pneumoniae in this setting is not guideline-supported
- Persistent pharyngitis or sinusitis unresponsive to standard therapy, where atypical pathogens are being ruled out
- Serial convalescent titre measurement to document a fourfold rise in IgG when acute infection is suspected but initial serology is equivocal
- Assessment of possible chronic C. pneumoniae carriage in functional-medicine or integrative contexts, recognising that the clinical significance of such findings is contested
Sample collection and turnaround
Sample type
Blood (serum)
Fasting required
No
Collection method
Venipuncture at patient service centre
Turnaround
3–5 business days
Collection notes
Phlebotomy via Quest patient service centre; no special preparation. For optimal diagnostic yield, collect acute-phase serum at symptom onset and convalescent serum two to four weeks later to demonstrate a fourfold or greater titre rise. Single time-point samples are less informative.
Specimen requirements
Minimum 1 mL serum; separate from cells and refrigerate or freeze if not processed immediately. Paired sera should be tested in parallel to reduce inter-assay variation.
What can affect C. pneumoniae Antibodies results?
More than half of adults carry detectable IgG from prior subclinical or clinical infection, so a single positive IgG does not confirm active disease; paired sera or clinical correlation is essential.
Shared chlamydial antigens can produce false-positive results, particularly for IgG and IgM, complicating interpretation when multiple exposures are possible.
Micro-immunofluorescence (MIF) is the reference standard but labour-intensive; enzyme immunoassays are more automated but vary in sensitivity and specificity, and no universal cut-off exists.
Antibodies may not be detectable in the first week of symptoms; late or convalescent sampling increases diagnostic yield, while very early sampling risks false negatives.
Blunted antibody responses in immunocompromised patients can result in false-negative serology despite active infection; direct detection methods (PCR) are preferable in such cases.
Non-specific immunoglobulin elevations and rheumatoid factor can produce false-positive IgM, a recognised pitfall in serological diagnosis of atypical infections.
What do C. pneumoniae Antibodies results mean?
Elevated
IgM positive or rising: suggests acute primary infection, though sensitivity is modest and false positives occur; pair with IgG and clinical findings. IgG positive (high titre) or fourfold rise: supports recent or past infection; in isolation, single positive IgG reflects prior exposure rather than active disease. IgA positive or persistently elevated: interpreted as a marker of active, recent, or chronic infection, particularly when IgG is also elevated; this pattern is seen in chronic respiratory syndromes and has been explored in cardiovascular and rheumatological contexts, though causal links remain investigational.
Normal
Negative results across all three classes make significant past or active C. pneumoniae infection unlikely, though very early acute infection and immunodeficiency are caveats. Equivocal results warrant repeat testing in two to four weeks.
Reduced
Negative IgG, IgA, and IgM: no serological evidence of C. pneumoniae infection; does not exclude very early infection (before seroconversion) or infection in an immunocompromised host with impaired antibody responses.
Note: Serology for C. pneumoniae is best interpreted with paired acute and convalescent samples to demonstrate a rising titre; single time-point results are of limited diagnostic value given high background seropositivity. Cross-reactivity, assay variability, and the absence of consensus diagnostic criteria complicate interpretation. When possible, complement serology with culture or PCR if available, and correlate findings with clinical presentation and epidemiology rather than relying on antibody titres alone.
Frequently asked questions
Chlamydophila pneumoniae is an obligate intracellular bacterium causing atypical community-acquired pneumonia, bronchitis, and pharyngitis, and investigated in chronic respiratory and systemic inflammatory conditions. Serology detects antibodies to support the diagnosis of acute or chronic infection.
How to access the C. pneumoniae Antibodies test
The C. pneumoniae Antibodies reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Grayston JT, et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis. (1990)
- Dowell SF, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis. (2001)
- Blasi F, et al. Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment. Thorax. (2002)
- Saikku P. Chlamydia pneumoniae: epidemiology, pathogenesis, and role in cardiovascular disease. Eur Heart J. (1993)
- Mandell LA, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. (2007)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.